Medical Equipment

Venture investment in biopharma and medtech companies has been continuing its upward trend through the first half of 2024. 

The total amount of capital invested in biopharma therapeutics and discovery platforms grew in the second quarter of 2024 and notched the highest quarterly investment total since the first quarter of 2022.  Medtech is also trending in a positive direction with 2024 on track to outpace the total amount of capital invested last year.

M&A activity has been gaining traction through the first half of the year as well; the total amount of medtech M&A deals through Q2 has nearly matched 2023’s full-year total.  

J.P. Morgan’s biopharma therapeutics and medtech licensing reports explore the movement in each sector, offering insight on industry and investment trends that defined the first half of 2024 and are shaping the remainder of 2024. The reports, powered by DealForma, highlight: 

  • Deal values in biopharma licensing partnerships
  • Trends in deal values for medical devices, diagnostics, digital health therapies and research tools
  • Venture investment amounts in therapeutic and platform companies
  • The advanced therapies that are seeing healthy investment and dealmaking
  • IPO and M&A activity in each sector

Download the full reports to better understand these dealmaking trends and reach out to J.P. Morgan to connect with a startup banking expert.

Contributors

Kathryn McDonough

Head of Life Sciences, Innovation Economy, Commercial Banking, J.P. Morgan

Skip Kelly

Head of Healthcare VC Coverage, Commercial Banking, J.P. Morgan